What is ctDNA testing and should Waldenstrom Macroglobulinemia patients get it

ctDNA Testing and Waldenstrom Macroglobulinemia

I appreciate your question about ctDNA testing for WM patients. Let me give you a straightforward answer based on current medical guidelines.

What is ctDNA Testing?

ctDNA stands for circulating tumor DNA. This is a blood test that detects tiny fragments of cancer cell DNA floating in your bloodstream. Think of it as a "liquid biopsy"—instead of taking tissue samples, doctors can detect cancer-related genetic material directly from blood.

The test can identify specific mutations or genetic changes that cancer cells carry, potentially helping doctors:

• Detect cancer earlier
• Monitor how well treatment is working
• Identify resistance to therapy before symptoms appear

Current Status for Waldenstrom Macroglobulinemia

Here's the important part: Based on the NCCN Guidelines for Waldenstrom Macroglobulinemia (Version 1.2026), ctDNA testing is not currently listed as a standard recommended test for WM diagnosis, monitoring, or treatment planning.

The NCCN Guidelines specify the essential and recommended testing for WM patients, which includes:

• Serum protein electrophoresis (SPEP) and immunofixation electrophoresis (SIFE) to measure IgM levels
• Bone marrow biopsy with flow cytometry
• MYD88 and CXCR4 mutation testing
• Imaging (CT/PET scans)
• Specialized tests for complications (neuropathy, amyloidosis, etc.)

ctDNA is not among these standard recommendations.

Why Isn't ctDNA Standard for WM Yet?

Several reasons:

1. WM has excellent existing biomarkers - Your serum IgM level is a highly reliable, well-established marker that doctors have used successfully for decades to monitor WM

2. Limited research in WM specifically - While ctDNA shows promise in other blood cancers, there isn't yet sufficient evidence demonstrating that ctDNA testing improves outcomes specifically for WM patients

3. Different disease biology - WM's slow growth pattern and the reliability of IgM monitoring may mean ctDNA offers less additional benefit compared to other lymphomas

What You Should Know

• If your doctor suggests ctDNA testing: This might be in the context of a clinical trial or for a specific clinical question. Ask your oncologist why they think it would be helpful in your particular situation.

• Your current monitoring is evidence-based: The tests your WM care team is using (IgM levels, bone marrow assessment, imaging) are the gold standard according to NCCN Guidelines and have strong evidence supporting their use.

• This may change: As research evolves, ctDNA testing might become incorporated into WM monitoring in the future. Medical guidelines are updated regularly as new evidence emerges.

Questions to Ask Your Care Team

1. "Are there any clinical trials involving ctDNA testing for WM that might be appropriate for me?"

2. "Why would ctDNA testing be helpful in monitoring my specific situation, given that my IgM levels are being tracked?"

3. "Are there any new biomarkers or tests you're considering for my care that might give us additional information?"

4. "How often should I have my standard monitoring tests (IgM, bone marrow biopsy, imaging) based on my current treatment status?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.